Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study
ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL
PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Dasatinib vs imatinib for paediatric Ph ALL
Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints
KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM
Moxetumomab pasudotox-tdfk in heavily retreated r/r hairy cell leukaemia
Azacitidine plus nivolumab in older adults with AML or MDS